Synaptica

Synaptica creates computational neuroscience tools to interpret ion channel mutations and guide personalized treatment strategies for associated diseases, specifically focusing on channelopathies. The company develops machine learning and functional models to interpret genetic ion channel variants, which supports the selection of effective, tailored treatments for individual patients. Synaptica offers solutions for healthcare providers to interpret missense variants in ion channels, which are often difficult to analyze. For the life sciences sector, the company specializes in the collection, curation, analysis, and interpretation of channelopathy-related biomedical datasets. Ion channels are a major drug target category, and Synaptica's expertise accelerates the identification of effective treatments for these disorders, addressing significant unmet medical needs with precision. The company's clinical decision support system, the Variant Interpreter, provides healthcare providers with actionable insights on disease-causing ion channel variants, enabling more informed treatment decisions for patients with channelopathies. Synaptica supports the interpretation of variants in over 100 ion channels and addresses 130 diseases.